Abstract
Purified human leukocyte interferon produced by recombinant techniques (IFN-αA) was tested in vitro with chemotherapeutic drugs, vinblastine (VLB), vincristine (VCR), vindesine (VDS), vinzolidine (VZL), cis-platinum (PLAT), doxorubicin (DOXO), etoposide (VP-16), and melphalan (MEL). The activity of these agents alone or in combination was tested against various human tumor cell lines, using a modified soft agar clonogenic assay. Three human tumor cell lines (myeloma, RPMI 8226; breast, MCF-7; and colon, WiDR) showed sensitivity to these agents at clinically achievable drug concentrations. Statistically significant synergistic activity against in vitro colony formation was observed with the combination of VLB and IFN-αA. An additive or sub-additive effect was usually observed with the other agents tested. Continuous exposure of the 8226 myeloma cell line to both IFN-αA and PLAT showed evidence of a more significant potentiation. It is hypothesized that the synergistic effect observed between VLB and IFN-αA is due to some of their common mechanisms of action.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 161-166 |
| Number of pages | 6 |
| Journal | Cancer Chemotherapy and Pharmacology |
| Volume | 10 |
| Issue number | 3 |
| DOIs | |
| State | Published - 1983 |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Oncology
- Pharmacology
Cite this
Interactions of human leukocyte interferon with vinca alkaloids and other chemotherapeutic agents against human tumors in clonogenic assay. / Aapro, Matti S.; Alberts, David S; Salmon, Sydney E.
In: Cancer Chemotherapy and Pharmacology, Vol. 10, No. 3, 1983, p. 161-166.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Interactions of human leukocyte interferon with vinca alkaloids and other chemotherapeutic agents against human tumors in clonogenic assay
AU - Aapro, Matti S.
AU - Alberts, David S
AU - Salmon, Sydney E.
PY - 1983
Y1 - 1983
N2 - Purified human leukocyte interferon produced by recombinant techniques (IFN-αA) was tested in vitro with chemotherapeutic drugs, vinblastine (VLB), vincristine (VCR), vindesine (VDS), vinzolidine (VZL), cis-platinum (PLAT), doxorubicin (DOXO), etoposide (VP-16), and melphalan (MEL). The activity of these agents alone or in combination was tested against various human tumor cell lines, using a modified soft agar clonogenic assay. Three human tumor cell lines (myeloma, RPMI 8226; breast, MCF-7; and colon, WiDR) showed sensitivity to these agents at clinically achievable drug concentrations. Statistically significant synergistic activity against in vitro colony formation was observed with the combination of VLB and IFN-αA. An additive or sub-additive effect was usually observed with the other agents tested. Continuous exposure of the 8226 myeloma cell line to both IFN-αA and PLAT showed evidence of a more significant potentiation. It is hypothesized that the synergistic effect observed between VLB and IFN-αA is due to some of their common mechanisms of action.
AB - Purified human leukocyte interferon produced by recombinant techniques (IFN-αA) was tested in vitro with chemotherapeutic drugs, vinblastine (VLB), vincristine (VCR), vindesine (VDS), vinzolidine (VZL), cis-platinum (PLAT), doxorubicin (DOXO), etoposide (VP-16), and melphalan (MEL). The activity of these agents alone or in combination was tested against various human tumor cell lines, using a modified soft agar clonogenic assay. Three human tumor cell lines (myeloma, RPMI 8226; breast, MCF-7; and colon, WiDR) showed sensitivity to these agents at clinically achievable drug concentrations. Statistically significant synergistic activity against in vitro colony formation was observed with the combination of VLB and IFN-αA. An additive or sub-additive effect was usually observed with the other agents tested. Continuous exposure of the 8226 myeloma cell line to both IFN-αA and PLAT showed evidence of a more significant potentiation. It is hypothesized that the synergistic effect observed between VLB and IFN-αA is due to some of their common mechanisms of action.
UR - http://www.scopus.com/inward/record.url?scp=0020635925&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0020635925&partnerID=8YFLogxK
U2 - 10.1007/BF00255753
DO - 10.1007/BF00255753
M3 - Article
C2 - 6861260
AN - SCOPUS:0020635925
VL - 10
SP - 161
EP - 166
JO - Cancer Chemotherapy and Pharmacology
JF - Cancer Chemotherapy and Pharmacology
SN - 0344-5704
IS - 3
ER -